PPaPS
You are here:
PPaPS Study (Persisting Psychedelic-associated Psychological Symptoms)
The PPaPS study aims to assess potential risks associated with the use of 5HT2a agonists (`psychedelics´). Psychedelics are considered to be relatively safe when ingested within a controlled setting, as they display low toxicity and no dependency potential. However, in rare cases, negative postacute effects such as anxiety, psychosis, dissociative symptoms or persisting changes in perception have been reported after the non-clinical use of those substances. To date, little is known about the causes and risk factors for such long-term effects. For instance, it is unclear in how far people with specific psychiatric or neurological disorders are at particular risk when using psychedelics and it has not yet been what role specific quality of the acute experiences play with regard to negative outcomes..
Therefore, in the PPaPS study, people affected by negative long-term consequences are retrospectively interviewed about their experiences with psychedelics, pre-existing conditions, and other characteristics. In order to design an instrument for the comprehensive and systematic assessment of long-term adverse effects, a psychometric tool will be designed and validated in a online-based survey. In addition, potential neurobiological changes will be investigated by magnetic resonance imaging and electroencephalography (EEG).
Leitung:
Dr. Tomislav Majić
Dr. med. Dipl.-Psych. Thomas Riemer
Mitarbeiterinnen:
Dipl.-Psych. Bente Lubahn
Dr. Marija Franka Žuljević
Dr. Derien Marbin
Dr. Dario Jalilzadeh Masah